ReviewThrombosis and haemostasis2020
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
Open access · bronzeAbstract readReview
In one paragraph
Review in Thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 5 pooled it
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 5 syntheses or guidelines pooled it, 253 citations in OpenAlex.
- Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report.Journal of medical case reports · 2022Pooled it
- Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials.Frontiers in medicine · 2022Pooled it
- 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary.Thrombosis and haemostasis · 2022Guideline
- A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy.Shock (Augusta, Ga.) · 2021Pooled it
- Pooled it
- Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.BMJ (Clinical research ed.) · 2022Trial
- Pulmonary Procoagulant and Innate Immune Responses in Critically Ill COVID-19 Patients.Frontiers in immunology · 2021Trial
- Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.International journal of clinical practice · 2020Trial
- Serum CD73 activity as a biomarker of hypoxemia in COVID-19 patients.Scientific reports · 2026Article
- Venous thromboembolism in hospitalized patients with COVID-19: clinical and laboratory characteristics at three tertiary care centers in a state capital in the Eastern Amazon.Jornal vascular brasileiro · 2026Article
- Distinct venous thrombotic phenotypes exist in the critically ill.Critical care science · 2026Review
- Inflammatory Milieu and Specific T-Cell Response Observed Three Months and One Year After SARS-CoV-2 Infection in Long COVID Subjects.International journal of molecular sciences · 2025Article
- Oral Anticoagulation Therapy: An Update on Usage and Costs in the Endemic COVID-19 Era.Journal of clinical medicine · 2025Article
- The Role of Sterile Inflammation in Thrombosis: Consequences for Cardiovascular Disease and COVID-19.Mediators of inflammation · 2025Review
- Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study.EClinicalMedicine · 2024Article
- Thromboinflammation and the Role of Platelets.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Postoperative thrombotic events following major surgery in patients with a history of COVID-19: a retrospective cohort analysis of commercially insured beneficiaries in the USA.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2024Article
- New-Onset Atrial Fibrillation in the Critically Ill COVID-19 Patients Hospitalized in the Intensive Care Unit.Journal of clinical medicine · 2023Review
- Effects of inflammation on thrombosis and outcomes in COVID-19: secondary analysis of the ATTACC/ACTIV-4a trial.Research and practice in thrombosis and haemostasis · 2023Article
- Pathological Effects of SARS-CoV-2 Associated with Hematological Abnormalities.Current issues in molecular biology · 2023Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors at 20 institutions in 13 countries.
Behnood BikdeliNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Mahesh V Madhavan *New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Aakriti GuptaNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
David JimenezRespiratory Department, Hospital Ramón y Cajal, Madrid, Spain.
John R BurtonNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Caroline Der NigoghossianNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Taylor ChuichNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Shayan Nabavi NouriNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Isaac DreyfusNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Elissa DrigginNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Sanjum SethiNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Kartik SehgalHarvard Medical School, Boston, Massachusetts, United States.
Saurav ChatterjeeNorth Shore and Long Island Jewish University Hospitals, Queens, New York, United States.
Walter AgenoDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Mohammad MadjidMcGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, United States.
Yutao GuoDepartment of Cardiology, Chinese PLA General Hospital, Beijing, China.ORCID 0000-0002-7626-7751
Liang V TangInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yu HuInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Laurent BertolettiDepartment of "Médecine Vasculaire et Thérapeutique," CIC 1408, INNOVTE, CHU de St-Etienne and INSERM UMR1059, Université Jean-Monnet, Saint-Etienne, France.ORCID 0000-0001-8214-3010
Jay GiriCardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Mary CushmanLarner College of Medicine, University of Vermont, Burlington, Vermont, United States.
Isabelle QuéréDepartment of Vascular Medicine, University of Montpellier, Montpellier CHU, InnoVTE F-CRIN Network, Montpellier, France.
Evangelos P DimakakosOncology Unit GPP, Sotiria General Hospital, Athens School of Medicine, Athens, Greece.
C Michael GibsonHarvard Medical School, Boston, Massachusetts, United States.
Giuseppe LippiLaboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy.
Emmanuel J FavaloroLaboratory Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia.
Jawed FareedLoyola University Medical Center, Chicago, Illinois, United States.
Alfonso J TafurPritzker School of Medicine at the University of Chicago, Chicago, Illinois, United States.
Dominic P FranceseClinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
Jaya BatraNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Anna FalangaDepartment of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, University of Milan Bicocca, Bergamo, Italy.
Kevin J ClerkinNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Nir UrielNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Ajay KirtaneNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Claire McLintockAuckland City Hospital, Auckland, New Zealand.
Beverley J HuntSt Thomas' Hospital, London, United Kingdom.
Alex C SpyropoulosThe Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York, United States.
Geoffrey D BarnesInstitute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, United States.
John W EikelboomPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
Ido WeinbergHarvard Medical School, Boston, Massachusetts, United States.
Sam SchulmanDepartment of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Marc CarrierThe Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Gregory PiazzaHarvard Medical School, Boston, Massachusetts, United States.
Joshua A BeckmanVanderbilt University School of Medicine, Nashville, Tennessee, United States.
Martin B LeonNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Gregg W StoneClinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
Stephan RosenkranzDepartment of Cardiology, Cologne Cardiovascular Research Center (CCRC), Heart Center at the University of Cologne, University of Cologne, Cologne, Germany.
Samuel Z GoldhaberHarvard Medical School, Boston, Massachusetts, United States.
Sahil A ParikhNew York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
Manuel MonrealDepartment of Internal Medicine, Hospital Universitari Germans Trials I Pujol, Universidad Católica de Murcia, Barcelona, Spain.
Harlan M KrumholzCenter for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, United States.
Stavros V KonstantinidesCenter for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany.ORCID 0000-0001-6359-7279
Jeffrey I WeitzMcMaster University, Hamilton, Ontario, Canada.
Gregory Y H LipLiverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.ORCID 0000-0002-7566-1626
Global COVID-19 Thrombosis Collaborative Group
NewYork–Presbyterian Hospital · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USCardiovascular Research Foundation · USUnion Hospital · CNUniversity of Liverpool · GBAuckland City Hospital · NZDonald & Barbara Zucker School of Medicine at Hofstra/Northwell · USHarvard University · USHospital of the University of Pennsylvania · USInserm · FRJohannes Gutenberg University Mainz · DELong Island Jewish Medical Center · USLoyola University Medical Center · USNorthShore University HealthSystem · USOttawa Hospital · CAPopulation Health Research Institute · CASechenov University · RUSotiria General Hospital · GRSt Thomas' Hospital · GB
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MIdentifying Novel Diagnostics and Mechanisms for Cardiac Allograft VasculopathyK23HL148528 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CLERKIN, KEVIN J · 2020 to 2024
$852kNCATS NIH HHS UL1 TR001863NHLBI NIH HHS K23 HL148528
Abstract
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.
Indexed as
AnimalsAnticoagulantsAnti-Inflammatory AgentsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentFibrinolytic AgentsGlycosaminoglycansHemostasisHumansInflammationPandemicsPlatelet Aggregation InhibitorsPneumonia, ViralAnticoagulantsAnti-Inflammatory AgentsAntiviral AgentsFibrinolytic Agentsglucuronyl glucosamine glycan sulfateGlycosaminoglycansPlatelet Aggregation Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.